The -c(=x)- Is Part Of A -c(=x)x- Group, Wherein The X's Are The Same Or Diverse Chalcogens Patents (Class 534/13)
-
Publication number: 20150147272Abstract: A tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand comprising four HOPO moieties and the ion of an alpha-emitting thorium radionuclide, where at least one of the four HOPO moieties is substituted at the N-position with a hydroxyalkyi solubilising group and wherein the tissue targeting moiety has binding affinity for the CD33 receptor. A corresponding pharmaceutical formulation and method and use in treatment, as well as methods of manufacture are provided.Type: ApplicationFiled: May 13, 2013Publication date: May 28, 2015Inventors: Hanne Therese Bonge-Hanssen, Olav Benjamin Ryan
-
Publication number: 20140308203Abstract: Provided herein are methods for delivering a molecule in situ to a cell and for treating a cancer via the in situ delivery. The methods comprise contacting or administering to the cell, as two separate components, a morpholino oligonucleotide comprising a targeting moiety followed by a single wall nanotube construct comprising second morpholino oligonucleotides complementary to the first morpholino oligonucleotides and one or both of a therapeutic or diagnostic payload molecule linked to the single wall nanotube construct. Upon self-assembly of a single wall nanotube complex via hybridization of the first morpholino and second complementary morpholino oligonucleotides at the cell, the payload molecule is delivered. Also provided is the two component self-assembly single wall nanotube system and the single wall nanotube construct comprising the second component.Type: ApplicationFiled: June 27, 2014Publication date: October 16, 2014Inventors: David A. Scheinberg, Michael R. McDevitt, Carlos H. Villa, J. Justin Mulvey
-
Publication number: 20140241985Abstract: Compounds as defined herein are provided which are useful in (1) diagnostic methods for detecting and/or identifying cells presenting PSMA; (2) compositions comprising a compound of the invention together with a pharmaceutically acceptable diluent; and (3) methods for imaging prostate cancer cells.Type: ApplicationFiled: June 13, 2012Publication date: August 28, 2014Applicant: CANCER TARGETED TECHNOLOGY LLCInventors: Clifford Berkman, Bea Langton-Webster, Xiaobing Wang
-
Publication number: 20140039169Abstract: The present invention provides luminescent complexes between a lanthanide ion and an organic ligand which contains 1,2-hydroxypyridinone units. The complexes of the invention are stable in aqueous solutions and are useful as molecular probes, for example in medical diagnostics and bioanalytical assay systems. The invention also provides methods of using the complexes of the invention.Type: ApplicationFiled: October 8, 2013Publication date: February 6, 2014Inventors: Kenneth N. RAYMOND, Jide Xu, Evan G. Moore, Eric J. Werner
-
Publication number: 20110263837Abstract: A method for preparing an oxalate of one or more actinides for processing and recycling nuclear fuel, comprising: the precipitation of said actinide or the coprecipitation of said actinides in the form of oxalate particles by bringing into contact an aqueous solution containing the actinide(s) with an aqueous solution of oxalic acid or of an oxalic acid salt; and the collection of the resulting oxalate particles; characterized in that the precipitation or coprecipitation is carried out in fluidized bed.Type: ApplicationFiled: December 17, 2009Publication date: October 27, 2011Inventors: Murielle Bertrand, Stephane Grandjean, Bruno Courtaud, Frederic Auger
-
Publication number: 20110180968Abstract: A method for making a carbon nanotube metal composite includes the following steps. A number of carbon nanotubes is dispersed in a solvent to obtain a suspension. Metal powder is added into the suspension, and then the suspension agitated. The suspension containing the metal powder is allowed to stand for a while. The solvent is reduced to obtain a mixture of the number of carbon nanotubes and the metal powder.Type: ApplicationFiled: October 15, 2010Publication date: July 28, 2011Applicants: TSINGHUA UNIVERSITY, HON HAI PRECISION INDUSTRY CO., LTD.Inventors: CHUN-HUA HU, CHANG-HONG LIU, SHOU-SHAN FAN
-
Patent number: 7198776Abstract: The invention relates to metal complex compounds, contrast agents for MRI and in vivo NMR markers for NMR spectroscopy comprising said metal complex compounds and methods for in vivo determination of physiological parameters, e.g. enzyme activity or pH using said metal complex compounds.Type: GrantFiled: November 28, 2002Date of Patent: April 3, 2007Assignee: GE Healthcare ASInventors: Jo Klaveness, Pal Rongved
-
Patent number: 7163935Abstract: Substituted 1,4,7-triazacyclononane-N,N?,N?-triacetic acid compounds with a pendant donor amino group, metal complexes thereof, compositions thereof, and methods of use in diagnostic imaging and treatment of a cellular disorder.Type: GrantFiled: June 3, 2003Date of Patent: January 16, 2007Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Martin W. Brechbiel, Hyun-Soon Chong
-
Patent number: 7081452Abstract: Substituted 1,4,7-triazacyclononane-N,N?,N?-triacetic acid compounds with a pendant donor amino group, metal complexes thereof, compositions thereof, and methods of use in diagnostic imaging and treatment of a cellular disorder.Type: GrantFiled: December 13, 2002Date of Patent: July 25, 2006Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Martin W. Brechbiel, Hyun-Soon Chong
-
Publication number: 20030108462Abstract: An environmentally benign process for remediating contaminated matter includes contact with a lixiviant. The lixiviant contains a chelating agent which chemically reacts with a selected contaminant, forming a chelate soluble within the lixiviant and thus extracting the selected contaminant from the matter. The lixiviant, including the chelate, is separated from the particulate matter, and chemically treated to demobilize the chelate. The selected contaminant is separated from the lixiviant and sent for disposal or further processing. The remidiated matter is also sent for disposal or further processing.Type: ApplicationFiled: December 6, 2002Publication date: June 12, 2003Inventor: Kazem Eradat Oskoui
-
Publication number: 20030023050Abstract: 225Ac complexes comprising a functionalized polyazamacrocyclic chelant compound of the formula I hereinbelow: 1Type: ApplicationFiled: February 27, 2002Publication date: January 30, 2003Inventors: R. Keith Frank, Garry E. Kiefer, Jaime Simon
-
Patent number: 6462192Abstract: Processes for the large scale production of tetrapyrrolic compounds useful as photosensitizers in photodynamic therapy, such as meso-formyl porphyrins, meso-acrylate porphyrins, purpurins and benzochlorins. In particular, tin ethyl etiopurpurin (SnET2) and the intermediates necessary for its production without chromatography are disclosed.Type: GrantFiled: January 23, 2001Date of Patent: October 8, 2002Assignee: Miravant Pharmaceuticals, Inc.Inventors: Byron C. Robinson, Barbara A. Garcia
-
Publication number: 20020058007Abstract: The present invention provides functionalized chelants and a method of treating cancerous cells with alpha particles comprising the step of administering a pharmacologically effective dose of an 225Ac conjugate comprising a functionalized chelant 1Type: ApplicationFiled: September 14, 2001Publication date: May 16, 2002Inventors: David Scheinberg, Michael McDevitt, Paul Borchardt, Dangshe Ma
-
Patent number: 6340560Abstract: An aminopolycarboxylic acid compound represented by the following formula or analogous thereof: The aminopolycarboxylic acid compound of the present invention can be used as a chelating agent for various metals, which is excellent in the biodegradability and masking effect on metals.Type: GrantFiled: October 7, 1998Date of Patent: January 22, 2002Assignee: Fuji Photo Film Co., Ltd.Inventors: Tadashi Inaba, Kiyoshi Morimoto, Shigeo Hirano
-
Publication number: 20010019709Abstract: The invention relates to compounds useful as radiosensitizers in tumor therapy.Type: ApplicationFiled: May 7, 1999Publication date: September 6, 2001Inventors: WERNER KRAUSE, RUEDIGER LAWACZECK
-
Patent number: 6207130Abstract: A method has been developed for the solution-based metal exchange of carboxylato-alumoxanes [Al(O)x(OH)y(O2CR)z]n with a wide range of metal cations. Metal-exchanged carboxylato-alumoxanes are new, particularly those in which about 10% to about 50% or more of the Al ions are exchanged for other metal ions. Additionally, the carboxylic acid ligands can be stripped from the boehmite core of metal-exchanged carboxylato-alumoxanes at low temperature leading to the formation of metal-exchanged boebmite particles. These new material phases can be used as intermediates for preparation of mixed metal aluminum oxide materials. Thermolysis of the metal-exchanged carboxylato-alumoxanes or metal-exchanged boehmite particles results in doped aluminas (M/Al2O3), binary (MAlOx), ternary (MM′AlOx) and even more complex metal aluminum oxide compounds, where M and M′ are metal ions other than those of aluminum and are preferably those of Lanthanide metals or transition metals.Type: GrantFiled: April 10, 1998Date of Patent: March 27, 2001Assignees: Rice University, TDA Research, Inc.Inventors: Aivaras Kareiva, Chuansheng Bai, Charles Jeffrey Harlan, D. Brent MacQueen, Andrew R. Barron, Ronald L. Cook
-
Patent number: 6191262Abstract: In the metallation of complexing agents such as DTPA-BMA with a lanthanide using a lanthanide oxide such as the lanthanide source, oxalic acid is used as a reaction accelerator.Type: GrantFiled: October 15, 1999Date of Patent: February 20, 2001Assignee: Nycomed Imaging AsInventors: Ole Homestad, Espen Myrbraten
-
Patent number: 6124491Abstract: The invention includes hydrolyzable and polymerizable silanes, methods of making them and using them to obtain silicic acid(hetero)polycondensates and silicic acid(hetero)polymerizates. The hydrolyzable and polymerizable silanes have the formula I, ##STR1## wherein A=O, S, NH or C(O)O; wherein B=a straight chain or branched organic residue with at least one C.dbd.C double bond and from 4 to 50 carbon atoms;R is an alkyl group, alkenyl group, aryl group, alkylaryl group or an arylalkyl group;R' is a substituted or unsubstituted alkylene group, arylene group, arylenealkylene group or alkylenearylene group each having zero to ten carbon atoms, with the proviso that the substituted groups each have at least one oxygen atom, sulfur atom and/or amine group substituent;R.sup.Type: GrantFiled: February 25, 1997Date of Patent: September 26, 2000Assignee: Fraunhofer-Gesellschaft Zur Forderung der AngewandtenInventors: Herbert Wolter, Werner Storch
-
Patent number: 6075130Abstract: The invention pertains to compounds for binding lanthanide ions and actinide ions. The invention further pertains to compounds for binding radionuclides, and to methods of making radionuclide complexes. Also, the invention pertains to methods of extracting radionuclides. Additionally, the invention pertains to methods of delivering radionuclides to target locations. In one aspect, the invention includes a compound comprising: a) a calix[n]arene group, wherein n is an integer greater than 3, the calix[n]arene group comprising an upper rim and a lower rim; b) at least one ionizable group attached to the lower rim; and c) an ion selected from the group consisting of lanthanide and actinide elements bound to the ionizable group.Type: GrantFiled: November 10, 1998Date of Patent: June 13, 2000Assignees: Battelle Memorial Institute, Idaho Research Foundation, Inc.Inventors: Xiaoyuan Chen, Chien M. Wai, Darrell R. Fisher
-
Patent number: 6072038Abstract: The invention relates to the field of radiation sensitizers and the use of texaphyrins for radiation sensitization and other conditions for which X-ray radiation has proven to be therapeutic.Type: GrantFiled: June 25, 1998Date of Patent: June 6, 2000Assignee: Board of Regents, The University of Texas SystemInventors: Jonathan L. Sessler, Tarak D. Mody, Gregory W. Hemmi
-
Patent number: 6025351Abstract: Families of Diels Alder adducts and of metal complexes of Diels Alder adducts, which are useful as particularly active compounds for use in photodynamic therapy, are disclosed. The Diels Alder adducts and a preferred family of metal complexes have the structures of Formulas 3 and 4, below: ##STR1## where R1, R2, R3 and R4 can be the same or different, and each is methyl, ethyl, an amino acid moiety which is a part of an amide produced by reaction between an amine function of a naturally occurring amino acid and a carbonyl function of the adduct, or a monoclonal antibody moiety which is attached to the adduct moiety through a carbonyl which is a part of an amide produced by reaction between an amine function of a monoclonal antibody and a CO.sub.2 R', CH.sub.2 CO.sub.2 R' or CH.sub.2 CH.sub.2 CO.sub.Type: GrantFiled: November 26, 1997Date of Patent: February 15, 2000Assignees: University of Toledo, Medical College of OhioInventors: Alan R. Morgan, Steven H. Selman
-
Patent number: 6022959Abstract: Texaphyrin metal complex-oligonucleotide and -oligonucleotide analog conjugates are provided where the texaphyrin is bound to an internal linkage of the oligonucleotide or oligonucleotide analog, the conjugates having catalytic activity for the hydrolysis of ribonucleic acid. Further, conjugates demonstrating catalytic turnover are described, the conjugates being especially effective under conditions where the concentration of RNA target exceeds that of available conjugate.Type: GrantFiled: November 20, 1997Date of Patent: February 8, 2000Assignee: Pharmacyclics, Inc.Inventors: Darren Magda, Shaun P. Crofts, Meredith Wright
-
Patent number: 5969111Abstract: Texaphyrins substituted with imidazda are provided.Type: GrantFiled: February 4, 1997Date of Patent: October 19, 1999Assignees: Board of Regents, The University of Texas System, Pharmacyclics, Inc.Inventors: Jonathan L. Sessler, Gregory W. Hemmi, Tarak D. Mody, Darren Magda, Vladimir A. Kral
-
Patent number: 5808013Abstract: Process for the preparation of N-alkyl substituted metal carbamate solutions characterized in that a water solution of the salt of the metal of which the corresponding carbamate is to be obtained, is reacted with an organic solution, basically consisting of an aprotic solvent and a secondary amine, saturated with carbon dioxide.The above solutions can be used as catalysts in polymerization reactions of unsaturated monomers or for supporting metals on inorganic oxides.Type: GrantFiled: July 10, 1996Date of Patent: September 15, 1998Assignee: Enichem S.p.A.Inventors: Paolo Biagini, Gabriele Lugli, Fausto Calderazzo, Daniela Belli Dell'Amico, Alessandra Merigo
-
Patent number: 5801229Abstract: Texaphyrins are provided for use as radiation sensitizers. Advantageous properties of texaphyrins for use as a radiation sensitizer include: i) a low redox potential which allows radiation-induced hydrated electrons to flow to texaphyrin rather than neutralizing hydroxyl radicals, allowing hydroxyl radicals to cause cellular damage, ii) a relatively stable texaphyrin radical that reacts readily to covalently modify neighboring molecules causing further cellular damage, iii) intrinsic biolocalization, and iv) indifference to the presence or absence of O.sub.2. These properties allow texaphyrins to be particularly effective for treating the hypoxic areas of solid neoplasms. Methods of treatment for an individual having a neoplasm or atheroma include the use of a texaphyrin as a radiation sensitizer and as an agent for photodynamic tumor therapy, or the use of a texaphyrin for internal and for external ionizing radiation. Novel texaphyrins are provided.Type: GrantFiled: September 13, 1996Date of Patent: September 1, 1998Assignee: The Board of Regents, University of Texas SystemInventors: Jonathan L. Sessler, Tarak D. Mody, Gregory W. Hemmi, Vladimir A. Kral
-
Patent number: 5789586Abstract: A method for preparing functionalized derivatives of organic or inorganic compounds and tetrapyrrolic compounds in particular, all of which compounds have at least one sulfonic acid group, by first preparing a sulfonyl halide intermediate of the compound then reacting the intermediate with a second compound having a reactive hydroxyl or amine group to yield the desired sulfonylamide or sulfonic esters thereof. The method may be used to produce a variety of photosensitive compounds having different functionality. For example, sulfonamide or sulfonic ester reaction products of the tetrapyrrolic compounds or other photosensitive organic molecules may exhibit an enhanced ability to localize at a particular target site for phototherapy.Type: GrantFiled: July 7, 1997Date of Patent: August 4, 1998Assignee: PDT Pharmaceuticals, Inc.Inventor: Byron Robinson
-
Patent number: 5783171Abstract: Chelating compounds of specified structure are useful for radiolabeling targeting proteins such as antibodies as well as proteinaceous and non-proteinaceous ligands and anti-ligands. The radiolabeled antibodies, ligands or anti-ligands, or catabolites thereof, demonstrate improved biodistribution properties, including reduced localization within the intestines.Type: GrantFiled: March 11, 1996Date of Patent: July 21, 1998Assignee: NeoRx CorporationInventors: Linda M. Gustavson, Sudhakar Kasina, Alan R. Fritzberg
-
Patent number: 5746995Abstract: The invention relates to new diethylenetriaminepentaacetic acid derivatives, their complexes and complex salts, that contain an element of atomic numbers 20-32, 39-51 or 57-83, pharmaceutical agents that contain these compounds and their use as contrast media and antidotes.Type: GrantFiled: November 30, 1995Date of Patent: May 5, 1998Assignee: Schering AktiengesellschaftInventors: Franz-Karl Maier, Michael Bauer, Werner Krause, Ulrich Speck, Gabriele Schuhmann-Giampieri, Andreas Muhler, Thomas Balzer, Wolf-Rudiger Press
-
Patent number: 5676923Abstract: Diethylenetriaminepentaacetic acid monoamide derivatives, their complexes and complex salts, containing an element of atomic numbers 21-29, 31, 32, 39, 42-44, 49 or 57-83, pharmaceutical agents containing these compounds, their use as contrast media and process for their production.Type: GrantFiled: June 7, 1995Date of Patent: October 14, 1997Assignee: Schering AktiengesellschaftInventors: Johannes Platzek, Ulrich Niedballa, Peter Mareski, Bernd Raduchel, Hanns-Joachim Weinmann, Andreas Muhler, Bernd Misselwitz
-
Patent number: 5633354Abstract: The invention is directed to a method of incorporating expanded porphyrins, and particularly of incorporating a sapphyrin or a texaphyrin, before, during, or after chemical synthesis of an oligomer to form an expanded porphyrin-oligonucleotide conjugate, and particularly a sapphyrin- or texaphyrin-oligonucleotide conjugate. This method includes reacting derivatized nucleotides and a sapphyrin or a texaphyrin in a desired order in an automated or manual DNA synthesizer having a solid support to form a sapphyrin- or a texaphyrin-oligonucleotide conjugate.Type: GrantFiled: March 13, 1996Date of Patent: May 27, 1997Assignees: Pharmacyclics, Inc., Board of Regents, The University of TexasInventors: Darren Magda, Jonathan L. Sessler, Brent L. Iverson, Petra I. Sansom, Shaun P. Crofts
-
Patent number: 5587371Abstract: Texaphyrins are provided for use as radiation sensitizers. Advantageous properties of texaphyrins for use as a radiation sensitizer include: i) a low redox potential which allows radiation-induced hydrated electrons to flow to texaphyrin rather than neutralizing hydroxyl radicals, allowing hydroxyl radicals to cause cellular damage, ii) a relatively stable texaphyrin radical that reacts readily to covalently modify neighboring molecules causing further cellular damage, iii) intrinsic biolocalization, and iv) indifference to the presence or absence of O.sub.2. These properties allow texaphyrins to be particularly effective for treating the hypoxic areas of solid neoplasms. Methods of treatment for an individual having a neoplasm or atheroma include the use of a texaphyrin as a radiation sensitizer and as an agent for photodynamic tumor therapy, or the use of a texaphyrin for internal and for external ionizing radiation. Novel texaphyrins are provided.Type: GrantFiled: June 2, 1995Date of Patent: December 24, 1996Assignees: Pharmacyclics, Inc., Board of Trustees, Univ. of TX Sys.Inventors: Jonathan L. Sessler, Tarak D. Mody, Gregory W. Hemmi, Vladimir A. Kr al, Darren Magda
-
Patent number: 5587394Abstract: Families of Diels Alder adducts and of metal complexes of Diels Alder adducts, which are useful as particularly active compounds for use in photodynamic therapy, are disclosed. The Diels Alder adducts and a preferred family of metal complexes have the structures of Formulas 1, 2, 3 and 4, below: ##STR1## where R1, R2, R3 and R4 can be the same or different, and each is methyl, ethyl or an amino acid moiety which is a part of an amide produced by reaction between an amine function of a naturally occurring amino acid and a carbonyl function of the adduct, R5, R6 and R7 can be the same or different, and each is ethyl or an amino acid moiety which is a part of an amide produced by reaction between an amine function of a naturally occurring amino acid and a carbonyl function of the adduct.Type: GrantFiled: June 7, 1995Date of Patent: December 24, 1996Assignees: The University of Toledo, Medical College of OhioInventors: Alan R. Morgan, Steven H. Selman
-
Patent number: 5580543Abstract: Texaphyrins are provided for use as radiation sensitizers. Advantageous properties of texaphyrins for use as a radiation sensitizer include: i) a low redox potential which allows radiation-induced hydrated electrons to flow to texaphyrin rather than neutralizing hydroxyl radicals, allowing hydroxyl radicals to cause cellular damage, ii) a relatively stable texaphyrin radical that reacts readily to covalently modify neighboring molecules causing further cellular damage, iii) intrinsic biolocalization, and iv) indifference to the presence or absence of O.sub.2. These properties allow texaphyrins to be particularly effective for treating the hypoxic areas of solid neoplasms. Methods of treatment for an individual having a neoplasm or atheroma include the use of a texaphyrin as a radiation sensitizer and as an agent for photodynamic tumor therapy, or the use of a texaphyrin for internal and for external ionizing radiation. Novel texaphyrins are provided.Type: GrantFiled: June 2, 1995Date of Patent: December 3, 1996Assignees: Pharmacyclics, Inc., Board of Regents, Univ. of Texas Sys.Inventors: Jonathan L. Sessler, Tarak D. Mody, Gregory W. Hemmi, Vladimir A. Kr al, Darren Magda
-
Patent number: 5565552Abstract: The invention is directed to a method of incorporating expanded porphyrins, and particularly of incorporating a sapphyrin or a texaphyrin, before, during, or after chemical synthesis of an oligomer to form an expanded porphyrin-oligonucleotide conjugate, and particularly a sapphyrin- or texaphyrin-oligonucleotide conjugate. This method includes reacting derivatized nucleotides and a sapphyrin or a texaphyrin in a desired order in an automated or manual DNA synthesizer having a solid support to form a sapphyrin- or a texaphyrin-oligonucleotide conjugate.Type: GrantFiled: June 7, 1995Date of Patent: October 15, 1996Assignees: Pharmacyclics, Inc., Board of Regents, Univ. of Texas Sys.Inventors: Darren Magda, Jonathan L. Sessler, Brent L. Iverson, Petra I. Sansom, Shaun P. Crofts
-
Patent number: 5563262Abstract: Families of Diels Alder adducts and of metal complexes of Diels Alder adducts, which are useful as particularly active compounds for use in photodynamic therapy, are disclosed. The Diels Alder adducts and a preferred family of metal complexes have the structures of Formulas 1, 2, 3 and 4, below: ##STR1## where R1, R2, R3 and R4 can be the same or different, and each is methyl, ethyl or an amino acid moiety which is a part of an amide produced by reaction between an amine function of a naturally occurring amino acid and a carbonyl function of the adduct, R5, R6 and R7 can be the same or different, and each is ethyl or an amino acid moiety which is a part of an amide produced by reaction between an amine function of a naturally occurring amino acid and a carbonyl function of the adduct, M comprises a metal cation, e.g., Sn or Zn, that is complexed with two of the nitrogens of the adduct, and R8 is an alkyl group other than t-butyl having from one to four carbon atoms.Type: GrantFiled: October 11, 1994Date of Patent: October 8, 1996Assignees: University of Toledo, Medical College of OhioInventors: Alan R. Morgan, Steven H. Selman
-
Patent number: 5531978Abstract: There are provided chelating agents particularly useful for the preparation of diagnostic and therapeutic agents for magnetic resonance imaging, scintigraphy, ultrasound imaging, radiotherapy and heavy metal detoxification, said agents being compounds of formula IX--CHR.sub.1 --NZ--(CHR.sub.1).sub.n --A--(CHR.sub.1).sub.m --NZ--CHR.sub.1 --X (I)wherein n and m are 2, 3 or 4; and A, X, R.sub.1 and Z are as defined in the specification.Type: GrantFiled: February 8, 1993Date of Patent: July 2, 1996Assignee: Nycomed Imaging ASInventors: Arne Berg, Torsten Almen, Jo Klaveness, Pal Rongved, Terje Thomassen, Harald Dugstad
-
Patent number: 5457183Abstract: A method of using texaphyrins as radiosensitizers. Advantageous properties of texaphyrins for use as a radiosensitizer include i) a low redox potential which allows radiation induced solvated electrons to flow to texaphyrin rather than neutralizing hydroxyl radicals, allowing the hydroxyl radicals to cause cellular damage, ii) a relatively stable texaphyrin radical which, nevertheless, reacts readily to covalently modify neighboring molecules causing further cellular damage, and iii) intrinsic biolocalization and indifference to the presence of O.sub.2 which allow texaphyrin to be particularly effective for treating the hypoxic areas of solid tumors. Sensitizer enhancement ratios of 1.62 and 2.2 were achieved at 20 .mu.M and 80 .mu.M gadolinium-texaphyrin, respectively, with a mouse leukemia cell line.Type: GrantFiled: October 12, 1993Date of Patent: October 10, 1995Assignee: Board of Regents, The University of Texas SystemInventors: Jonathan L. Sessler, Tarak D. Mody, Gregory W. Hemmi, Vladimir Kral
-
Patent number: 5419894Abstract: Compounds of the general formula I: ##STR1## wherein R.sup.1 signifies a COOX group or the group ##STR2## R.sup.2 and R.sup.3 are the same or different and signify a hydrogen atom, a lower straight- or branched-chain, hydrocarbon radical, a phenyl or benzyl group or either R.sup.2 or R.sup.3 signifies the group ##STR3## or R.sup.2 or R.sup.3 together signify a trimethylene or tetramethylene radical, R.sup.4 represents a straight- or branched-chain mono- or poly-hydroxyalkyl radical, R.sup.5 represents a hydrocarbon atom, a lower straight- or branched-chain, optionally mono- or poly-hydroxylated, hydrocarbon radical, Q signifies an oxygen or sulfur atom or the group ##STR4## and X represents hydrogen atoms and/or metal ion equivalents, and their salts with physiologically harmless organic bases, are valuable complexing agents, complexes and complex salts for diagnostic imaging.Type: GrantFiled: March 28, 1994Date of Patent: May 30, 1995Assignee: Schering AktiengesellschaftInventors: Heinz Gries, Franz-Josef Renneke, Hanns-Joachim Weinmann
-
Patent number: 5374416Abstract: The invention relates to ligands of formula ##STR1## in which B represents an ##STR2## W representing the ##STR3## group, in which groups X and Z represent a heterocycle. The invention also relates to the monometallic or polymetallic complexes formed by these ligands with metal ions chosen from lanthanide ions, transition metal ions. barium, bismuth, lead and the radioisotopes .sup.99m Tc, .sup.111 In, .sup.90 Y, .sup.64 Cu and .sup.169 Yb, as well as the physiologically acceptable salts of these complexes.The salts of these complexes may be used as diagnostic or therapeutic agents in nuclear magnetic resonance imaging and X-ray radiology, as in-vivo chemical shift agents and in nuclear medicine.Type: GrantFiled: November 17, 1992Date of Patent: December 20, 1994Assignee: Guerbet S.A.Inventors: Olivier Rousseaux, Michel Schaefer, Anne Bouillot, Dominique Meyer
-
Patent number: 5371234Abstract: .beta.-hydroxyhistidine, 4-(1-hydroxy-1-alkyl)imidazole or derivatives thereof can be used as a bidentate ligand in the chelation of iron(III), Al(III), Cr(III), Ga(III) and the actinides(IV), such as plutonium 238. .beta.-hydroxyhistidine is found in a pyoverdine-type siderophore produced by Pseudomonas fluorescens 244.Type: GrantFiled: September 23, 1992Date of Patent: December 6, 1994Assignee: The Unites States of America as represented by the Secretary of CommerceInventor: Diane K. Hancock
-
Patent number: 5369101Abstract: The present invention involves a novel tripyrrole dimethine-derived "expanded porphyrin" (texaphyrin), the synthesis of such compounds, their analogs or derivatives and their uses. These expanded porphyrin-like macrocycles are efficient chelators of divalent and trivalent metal ions. Metal complexes of these compounds are active as photosensitizers for the generation of singlet oxygen and thus potentially for inactivation or destruction of human immunodeficiency virus (HIV-1), mononuclear or other cells infected with such virus and tumor cells as well. A variety of texaphyrin derivatives have been produced and many more are readily obtainable. Various metal (e.g., transition, main group, and lanthanide) complexes with the texaphyrin and texaphyrin derivatives of the present invention have unusual water solubility and stability which render them particularly useful. These metallotexaphyrin complexes have optical properties making them unique as compared to existing porphyrin-like or other macrocycles.Type: GrantFiled: December 16, 1993Date of Patent: November 29, 1994Assignee: Board of Regents, The University of Texas SystemInventors: Jonathan L. Sessler, Gregory W. Hemmi, Toshiaki Murai
-
Patent number: 5328992Abstract: Compounds of the formula ##STR1## in which R is alkyl having up to 4 carbon atoms, n has an average value of at least 9, X is a radical of the formula --C(.dbd.O)--(NH--SO.sub.2).sub.m -- in which m is 0 or 1 and, if m is 1, the carhonyl group may be bonded to the oxygen atom or to the nitrogen atom, and each of the radicals A.sub.1, A.sub.2 and A.sub.3, independently of the others, is hydrogen or an acyl radical, and salts of salt-forming compounds of formula I, as well as metal complexes of compounds of formula I, in which A.sub.1, A.sub.2 and A.sub.3 are hydrogen can be used as metal chelators and as auxiliaries in diagnosis.Type: GrantFiled: October 27, 1992Date of Patent: July 12, 1994Assignee: Ciba-Geigy Corp.Inventors: Heinrich Peter, Theophile Moerker
-
Patent number: 5250668Abstract: A family of benzochlorins, a family of verdins, a family of porphyrin derivatives and metal complexes thereof are disclosed. The benzochlorins have the formula of FIG. 3 of the attached drawings; their metal complexes have the formula of FIG. 1 . The verdins have the formulas of FIGS. 4 and 6 of the attached drawings; their metal complexes have the formulas of FIGS. 2 and 5. The porphyrin derivatives have the formula of FIG. 9 of the attached drawings; their metal complexes have the formula of FIG. 10 . Solutions of the benzochlorins, verdins, porphyrin derivatives and metal complexes which are physiologically acceptable for intravenous administration are also disclosed, as are emulsions or suspensions of the solutions, and compositions which additionally include cyclodextrin, and wherein the molecules of the benzochlorin, verdin, porphyrin derivative or metal complex are encapsulated within the molecules of the cyclodextrin.Type: GrantFiled: January 8, 1992Date of Patent: October 5, 1993Inventors: Alan R. Morgan, Steven H. Selman
-
Patent number: 5217706Abstract: Novel magnetic resonance imaging agents comprise complexes of paramagnetic ions with hydrazide derivatives of polyaminocarboxylic acid chelating agents. These novel imaging agents are characterized by excellent NMR image-contrasting properties and by high solubilities in physiological solutions.A novel method of performing an NMR diagnostic procedure involves administering to a warm-blooded animal an effective amount of a complex as described above and then exposing the warm-blooded animal to an NMR imaging procedure, thereby imaging at least a portion of the body of the warm-blooded animal.Type: GrantFiled: June 3, 1992Date of Patent: June 8, 1993Assignee: Mallinckrodt Medical, Inc.Inventors: Raghavan Rajagopalan, Rebecca A. Wallace, Muthunadar P. Periasamy
-
Patent number: 5198208Abstract: There are provided chelating agents particularly useful for the preparations of diagnostic and therapeutic agents for magnetic resonance imaging, scintigraphy, ultrasound imaging, radiotherapy and heavy metal detoxification, said agents being compounds of formula X--CHR.sub.1 --NZ--(CHR.sub.1).sub.n --A--(CHR.sub.1).sub.m --NZ--CHR.sub.1 --X wherein (each of the groups Z is a group --CHR.sub.1 X or the groups Z together are a group --(CHR.sub.1).sub.q --A'--(CHR.sub.1).sub.r --, where A' is an oxygen or sulphur atom or a group --N--Y; A is a group --N--Y or A--(CHR.sub.1).sub.m -- represents a carbon-nitrogen bond or, when the groups Z together are a group --(CHR.sub.1).sub.q --A'--(CHR.sub.1).sub.r --, A may also represent an oxygen or sulphur atom; each Y, which may be the same or different, is a group --(CHR.sub.1).sub.p --N(CHR.sub.1 X).sub.2 or a group --CHR.sub.1 X; each X, which may be the same or different, is a carboxyl group or a derivative thereof or a group R.sub.1 ; each R.sub.Type: GrantFiled: March 16, 1990Date of Patent: March 30, 1993Assignee: Nycomed Imaging ASInventors: Arne Berg, Torsten Almen, Jo Klaveness, Pal Rongved, Terje Thomassen
-
Patent number: 5141740Abstract: Novel magnetic resonance imaging agents comprise complexes of paramagnetic ions with hydrazide derivatives of polyaminocarboxylic acid chelating agents. These novel imaging agents are characterized by excellent NMR image-contrasting properties and by high solubilities in physiological solutions. A novel method of performing an NMR diagnostic procedure involves administering to a warm-blooded animal an effective amount of a complex as described above and then exposing the warm-blooded animal to an NMR imaging procedure, thereby imaging at least a portion of the body of the warm-blooded animal.Type: GrantFiled: November 21, 1990Date of Patent: August 25, 1992Assignee: Mallinckrodt Medical, Inc.Inventors: Raghavan Rajagopalan, Rebecca A. Wallace, Muthunadar P. Periasamy
-
Patent number: 5109129Abstract: A family of benzochlorins, a family of verdins, a family of porphyrin derivatives and metal complexes thereof are disclosed. the benzochlorins have the formula of FIG. 3 of the attached drawings; their metal complexes have the formula of FIG. 1. The verdins have the formula of FIG. 4 of the attached drawings; their metal complexes have the formula of FIG. 2. The porphyrin derivatives have the formula of FIG. 9 of the attached drawings; their metal complexes have the formula of FIG. 10. Solutions of the benzochlorins, verdins, porphyrin derivatives and metal complexes which are physiologically acceptable for intravenous administration are also disclosed, as are emulsions or suspensions of the solutions, and compositions which additionally include cyclodextrin, and wherein the molecules of the benzochlorin, verdin, prophyrin derivative or metal complex are encapsulated within the molecules of the cyclodextrin. The solvent for the solutions can be a product of the reaction of ethylene oxide with castor oil.Type: GrantFiled: August 3, 1990Date of Patent: April 28, 1992Assignee: The University of Toledo, Medical College of OhioInventors: Alan R. Morgan, Steven H. Selman
-
Patent number: 4988808Abstract: A family of benzochlorins, a family of verdins, a family of porphyrin derivatives and metal complexes thereof are disclosed. The benzochlorins have the formula of FIG. 3 of the attached drawings; their metal complexes have the formula of FIG. 1. The verdins have the formula of FIG. 4 of the attached drawings; their metal complexes have the formula of FIG. 2. The porphyrin derivatives have the formula of FIG. 9 of the attached drawings; their metal complexes have the formula of FIG. 10. Solutions of the benzochlorins, verdins, porphyrin derivatives and metal complexes which are physiologically acceptable for intravenous administration are also disclosed, as are emulsions or suspensions of the solutions, and compositions which additionally include cyclodextrin, and wherein the molecules of the benzochlorin, verdin, porphyrin derivatives or metal complex are encapsulated within the molecules of the cyclodextrin. The solvent for the solutions can be a product of the reaction of ethylene oxide with castor oil.Type: GrantFiled: December 11, 1989Date of Patent: January 29, 1991Assignees: The University of Toledo, Medical College of OhioInventors: Alan R. Morgan, Steven H. Selman
-
Patent number: RE44338Abstract: This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.Type: GrantFiled: July 17, 2012Date of Patent: July 2, 2013Assignee: The Trustees Of The University Of PennsylvaniaInventors: Hank F. Kung, Mei-Ping Kung, Zhi-Ping Zhuang, Virginia M. Y. Lee, John Q. Trojanowski, Daniel M. Skovronsky
-
Patent number: RE44354Abstract: This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form-amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.Type: GrantFiled: July 17, 2012Date of Patent: July 9, 2013Assignee: The Trustees Of The University Of PennsylvaniaInventors: Hank F. Kung, Mei-Ping Kung, Zhi-Ping Zhuang, Virginia M. Y. Lee, John Q. Trojanowski, Daniel M. Skovronsky